LungLife AI Inc Asset Resilience Ratio
LungLife AI Inc asset resilience ratio. LungLife AI Inc (LLAI) has an Asset Resilience Ratio of 1.09% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can LungLife AI Inc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of LungLife AI Inc (2021–2023)
Asset resilience ratio of LungLife AI Inc from 2021 to 2023. This chart shows how LungLife AI Inc's Asset Resilience Ratio has changed over time. Read LLAI total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down LungLife AI Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see LungLife AI Inc (LLAI) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX104.00K | 1.09% |
| Total Liquid Assets | GBX104.00K | 1.09% |
Asset Resilience Insights
- Limited Liquidity: LungLife AI Inc maintains only 1.09% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
LungLife AI Inc Industry Peers by Asset Resilience Ratio
Compare LungLife AI Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716 |
Diagnostics & Research | 0.16% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193 |
Diagnostics & Research | 70.50% |
|
Krsnaa Diagnostics Limited
NSE:KRSNAA |
Diagnostics & Research | 9.90% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
LungLife AI Inc Asset Resilience Ratio by Year (2021–2023)
LungLife AI Inc asset resilience ratio by year from 2021 to 2023. The table below shows the annual Asset Resilience Ratio data for LungLife AI Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 1.09% | GBX104.00K ≈ $12.65 |
GBX9.52 Million ≈ $1.16K |
-31.68pp |
| 2022-12-31 | 32.77% | GBX4.92 Million ≈ $598.87 |
GBX15.02 Million ≈ $1.83K |
+8.14pp |
| 2021-12-31 | 24.63% | GBX5.41 Million ≈ $658.36 |
GBX21.97 Million ≈ $2.67K |
-- |
About LungLife AI Inc
LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People's Republic of China. The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, I… Read more